Heartland Advisors’s Harvard Bioscience HBIO Stock Holding History

Heartland Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-110,858	Closed	-$627K	–	218
2025 Q1	$627K	Sell	110,858 -9,142	-8%	-$117K	0.04%	199
2024 Q4	$2.53M	Hold	120,000	–	–	0.14%	162
2024 Q3	$3.23M	Hold	120,000	–	–	0.17%	151
2024 Q2	$3.42M	Buy	120,000 +31,087	+35%	+$1.09M	0.19%	143
2024 Q1	$3.77M	Buy	88,913 +2,266	+3%	+$102K	0.2%	146
2023 Q4	$4.64M	Hold	86,647	–	–	0.24%	137
2023 Q3	$3.73M	Buy	86,647 +1,647	+2%	+$76K	0.21%	145
2023 Q2	$4.67M	Sell	85,000 -35,000	-29%	-$1.92M	0.27%	132
2023 Q1	$5.04M	Buy	120,000 +8,560	+8%	+$254K	0.31%	130
2022 Q4	$3.09M	Buy	111,440 +6,440	+6%	+$159K	0.2%	149
2022 Q3	$2.69M	Buy	105,000 +41,841	+66%	+$1.38M	0.2%	149
2022 Q2	$2.27M	Buy	63,159 +23,159	+58%	+$1.05M	0.16%	163
2022 Q1	$2.48M	Hold	40,000	–	–	0.15%	165
2021 Q4	$2.82M	Hold	40,000	–	–	0.17%	168
2021 Q3	$2.79M	Sell	40,000 -35,000	-47%	-$2.79M	0.17%	183
2021 Q2	$6.25M	Sell	75,000 -20,000	-21%	-$1.41M	0.36%	123
2021 Q1	$5.19M	Sell	95,000 -1,140	-1%	-$55.5K	0.33%	128
2020 Q4	$4.12M	Hold	96,140	–	–	0.29%	136
2020 Q3	$2.89M	Sell	96,140 -3,860	-4%	-$130K	0.25%	140
2020 Q2	$3.1M	Hold	100,000	–	–	0.28%	135
2020 Q1	$2.21M	Hold	100,000	–	–	0.24%	141
2019 Q4	$3.05M	Hold	100,000	–	–	0.22%	144
2019 Q3	$3.08M	Hold	100,000	–	–	0.23%	144
2019 Q2	$2M	Hold	100,000	–	–	0.15%	158
2019 Q1	$4.31M	Sell	100,000 -10,778	-10%	-$391K	0.32%	130
2018 Q4	$3.52M	Hold	110,778	–	–	0.29%	128
2018 Q3	$5.82M	Sell	110,778 -28,665	-21%	-$1.61M	0.39%	114
2018 Q2	$7.46M	Sell	139,443 -15,857	-10%	-$812K	0.49%	95
2018 Q1	$7.76M	Sell	155,300 -14,323	-8%	-$642K	0.52%	86
2017 Q4	$5.6M	Sell	169,623 -30,377	-15%	-$1.03M	0.36%	116
2017 Q3	$7.5M	Sell	200,000 -10,000	-5%	-$296K	0.48%	103
2017 Q2	$5.36M	Hold	210,000	–	–	0.34%	127
2017 Q1	$5.46M	Buy	210,000 +10,000	+5%	+$288K	0.33%	130
2016 Q4	$6.1M	Sell	200,000 -30,000	-13%	-$763K	0.34%	130
2016 Q3	$6.26M	Buy	230,000 +10,000	+5%	+$278K	0.36%	118
2016 Q2	$6.29M	Buy	220,000 +14,578	+7%	+$464K	0.35%	115
2016 Q1	$6.2M	Buy	205,422 +5,422	+3%	+$154K	0.33%	115
2015 Q4	$6.94M	Buy	200,000 +100,000	+100%	+$3.42M	0.28%	116
2015 Q3	$3.78M	Hold	100,000	–	–	0.14%	158
2015 Q2	$5.7M	Hold	100,000	–	–	0.16%	158
2015 Q1	$5.82M	Buy	100,000 +70,000	+233%	+$3.76M	0.15%	153
2014 Q4	$1.7M	Hold	30,000	–	–	0.03%	233
2014 Q3	$1.23M	Buy	+30,000	New	+$1.38M	0.02%	234

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Heartland Advisors's HBIO Position: Q2 2025 in Review

Heartland Advisors sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 110,858 shares — an estimated $627K sold.

Heartland Advisors first reported a position in HBIO in Q3 2014 and held it in 43 quarters. The position peaked at $7.76M in Q1 2018. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

Heartland Advisors reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
Heartland Advisors sold 110,858 Harvard Bioscience shares in Q2 2025, an estimated $627K.
Heartland Advisors first reported a position in Harvard Bioscience in Q3 2014 and held it in 43 quarters.
Heartland Advisors's Harvard Bioscience position peaked at $7.76M in Q1 2018.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Heartland Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.